Accordingly, HCV-E2 augmented the expression of miR-490 in recipient HCC cells and MC-derived Exos, which mitigated the activity of the EGFR/AKT/ERK1/2 pathway, and prevented the migration of the HCC cells. Here, EGFR is linked to hepatocellular carcinoma.